Abbott Laboratories

Abbott Laboratories Equity

The The Equity of Abbott Laboratories (ABT) as of Nov 7, 2026 is 52.13 B USD. In the previous year, The Equity was 47.66 B USD — a change of 9.37% (higher).

Equity

52.13 BUSD

YoY

9.37%

Last updated:

In 2025, Abbott Laboratories's equity was 52.13 B USD, a 9.37% increase from the 47.66 B USD equity in the previous year.

The Abbott Laboratories Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
30.52 B USD
Jan 1, 2019
31.09 B USD
Jan 1, 2020
32.78 B USD
Jan 1, 2021
35.80 B USD
Jan 1, 2022
36.69 B USD
Jan 1, 2023
38.60 B USD
Jan 1, 2024
47.66 B USD
Jan 1, 2025
52.13 B USD
The Abbott Laboratories Equity history
YEAREquityYoY
52.13 BUSD+9.37%
47.66 BUSD+23.47%
38.60 BUSD+5.23%
36.69 BUSD+2.47%
35.80 BUSD+9.21%
32.78 BUSD+5.46%
31.09 BUSD+1.85%
30.52 BUSD-1.21%
30.90 BUSD+50.44%
20.54 BUSD-3.17%
21.21 BUSD-1.46%
21.53 BUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Abbott Laboratories Stock analysis

What does Abbott Laboratories do? Abbott Laboratories is one of the largest companies in the healthcare industry worldwide. The company was founded in 1888 by Dr. Wallace C. Abbott, who aimed to develop innovative and high-quality medical products that would improve people's lives and treat illnesses. Abbott Laboratories' business model is based on the discovery, development, manufacturing, and marketing of healthcare products. These range from pharmaceuticals to diagnostic devices. The company operates in various areas, including pharmaceuticals, nutrition, diagnostics, medical technology, and animal health. In the pharmaceutical field, Abbott Laboratories is a leading provider of generic drugs as well as innovative medications specialized in treating conditions such as Parkinson's disease, cancer, or hypertension. The company is particularly known for developing medications focused on the medical needs of women, such as hormone replacement therapy or birth control pills. In the nutrition field, Abbott Laboratories leads in the development of food and supplements for specific target groups, such as premature infants, cancer patients, or those with digestive problems. Best-selling products include Similac baby formula and Ensure, a nutritional supplement for older adults. In the diagnostics field, Abbott Laboratories develops and manufactures medical diagnostic devices and systems for patient monitoring. This includes blood glucose meters, blood pressure monitors, test strips, and laboratory systems for diagnosing diseases such as diabetes, HIV, or hepatitis. Abbott Laboratories is also a significant player in the medical technology field. The company produces and distributes medical devices such as pacemakers, stents, or artificial joints. These are typically used by doctors and hospitals to optimize patient treatment. In the animal health field, Abbott Laboratories offers a wide range of products and services for agricultural farms and veterinarians. This includes animal medications, pet food, diagnostics, and other services aimed at maintaining the health and well-being of livestock. Over the years, Abbott Laboratories has received numerous awards for its products and achievements. The company is committed to improving the quality of life for people worldwide and contributes to optimizing healthcare. Abbott Laboratories is among the top 15 leading pharmaceutical and healthcare companies worldwide and currently employs around 103,000 people in over 160 countries. Abbott Laboratories is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Abbott Laboratories's Equity

Abbott Laboratories's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Abbott Laboratories's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Abbott Laboratories's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Abbott Laboratories's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Abbott Laboratories’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Abbott Laboratories stock

The Equity of Abbott Laboratories is 52.13 B USD in 2025.

The Equity of Abbott Laboratories changed from 47.66 B USD to 52.13 B USD, representing a 9.37% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Abbott Laboratories since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Abbott Laboratories historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Abbott Laboratories

All Key Metrics — Abbott Laboratories